Ignyta Names Senior VP, Chemistry & Manufacturing

Ignyta, Inc., a precision oncology biotechnology company, has appointed Dr Valerie Harding to the newly created role of senior vice-president, chemistry, manufacturing, and controls. Harding joins Ignyta from Pfizer, where she held many roles including vice-president of product differentiation, vice-president of drug product design and vice-president of pharmaceutical development. Prior to Pfizer, Harding spent three years as a scientist and team leader at Boots and Company, preceded by three years as a tutor and researcher at the University of Nottingham's School of Pharmacy. Harding holds a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham and a B.S. in Pharmacy from the University of London.

Ignyta, Inc., a precision oncology biotechnology company, has appointed Dr Valerie Harding to the newly created role of senior vice-president, chemistry, manufacturing, and controls. Harding joins Ignyta from Pfizer, where she held many roles including vice-president of product differentiation, vice-president of drug product design and vice-president of pharmaceutical development. Prior to Pfizer, Harding spent three years as a scientist and team leader at Boots and Company, preceded by three years as a tutor and researcher at the University of Nottingham's School of Pharmacy. Harding holds a Ph.D. in Pharmaceutical Microbiology from the University of Nottingham and a B.S. in Pharmacy from the University of London.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By 

Lynkuet will compete with Astellas's Veozah/Veoza

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.